Prenetics (PRE)’ IM8 announced a collaboration through a know-how agreement with Mayo Clinic to develop a new generation of premium supplements. The collaboration will focus on creating evidence-based, clinically researched supplements designed to address key health priorities such as optimal nutrition, cellular rejuvenation, protein support, collagen health, muscle recovery, and overall well-being. The work seeks to ensure that every product developed meets the highest standards of science and efficacy, empowering individuals to take charge of their health with confidence. The collaboration includes contributions from Dawn Mussallem, M.D., a Mayo Clinic integrative oncologist and a member of IM8’s Scientific Advisory Board. Dr. Mussallem’s unique medical insights will guide the development of supplements that address key health priorities with precision and scientific rigor.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on PRE:
- Prenetics Global Announces 2024 Annual General Meeting
- Prenetics’ IM8, University of Oxford begin space experiment
- Prenetics Reports Strong Growth with New Launches
- Prenetics reports Q3 EPS (84c) vs. (98c) last year
- Prenetics reiterates FY24 revenue target exceeding $33M
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
